Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 159

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line models

Open access
Xintaropoulou, Chrysi, Ward, Carol, Wise, Alan, Marston, Hugh, Turnbull, Arran, Langdon, Simon P. · 2015 · Oncotarget

Abstract

// Chrysi Xintaropoulou 1 , Carol Ward 1 , Alan Wise 2 , Hugh Marston 2, 4 , Arran Turnbull 3 , Simon P. Langdon 1 1 Division of Pathology, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, EH4 2XU, UK 2 IOMET Pharma, Nine, Edinburgh BioQuarter, Edinburgh, EH16 4UX, UK 3 Breakthrough Breast Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, EH4 2XU, UK 4 Current Address: Eli Lilly Research and Development, Windlesham, Surrey, GU20 6PH, UK Correspondence to: Simon P. Langdon, e-mail: Simon.Langdon@ed.ac.uk Keywords: glycolysis, inhibitors, ovarian cancer, breast cancer Received: May 12, 2015 Accepted: June 29, 2015 Published: July 16, 2015 ABSTRACT Many cancer cells rely on aerobic glycolysis for energy production and targeting of this pathway is a potential strategy to inhibit cancer cell growth. In this study, inhibition of five glycolysis pathway molecules (GLUT1, HKII, PFKFB3, PDHK1 and LDH) using 9 inhibitors (Phloretin, Quercetin, STF31, WZB117, 3PO, 3-bromopyruvate, Dichloroacetate, Oxamic acid, NHI-1) was investigated in panels of breast and ovarian cancer cell line models. All compounds tested blocked glycolysis as indicated by increased extracellular glucose and decreased lactate production and also increased apoptosis. Sensitivity to several inhibitors correlated with the proliferation rate of the cell lines. Seven compounds had IC 50 values that were associated with each other consistent with a shared mechanism of action. A synergistic interaction was revealed between STF31 and Oxamic acid when combined with the antidiabetic drug metformin. Sensitivity to glycolysis inhibition was also examined under a range of O 2 levels (21% O 2 , 7% O 2 , 2% O 2 and 0.5% O 2 ) and greater resistance to the inhibitors was found at low oxygen conditions (7% O 2 , 2% O 2 and 0.5% O 2 ) relative to 21% O 2 conditions. These results indicate growth of breast and ovarian cancer cell lines is dependent on all the targets examined in the glycolytic pathway with increased sensitivity to the inhibitors under normoxic conditions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.4499

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

Metadata

Authors
Xintaropoulou, C., Ward, C., Wise, A., Marston, H., Turnbull, A., & Langdon, S. P.
Venue
Oncotarget
Published
2015-07-16
Volume
6
Issue
28
Pages
25677-25695
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1941490733
Cited by
159
References
6
FWCI
4.32
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.